Oss, September 25th, 2018 – In the Kinase Inhibitor symposium of the Discovery on Target conference, held in Boston this week, Dr. Guido Zaman will present the Oncolines™ profiling of all kinase inhibitors that have been approved for clinical use. New drug response biomarkers were identified by the genomic biomarker analysis that is an integral part of Oncolines™. The cancer cell line profiling data is complemented with biochemical assay data on 280 kinases performed at Carna Biosciences, Inc.
Symposium: Kinase Inhibitor Discovery
Title: Full kinome and cancer cell panel profiling of all kinase inhibitor drugs approved for clinical use
Presenter: Dr. Guido Zaman
Date: Thursday, September, 27th, 2018
Time: 5.30 p.m.
Heat map showing the Oncolines™ profiles of recently approved kinase inhibitor drugs for oncology
NTRC is a precision medicine company dedicated to the development of new anti-cancer drugs. NTRC facilitates the development of novel therapies by providing cancer cell line profiling services (Oncolines™, OncolinesProfiler™, GeneNominator™, SynergyFinder™ and SynergyScreen™) and target residence time measurements for protein kinases (ResidenceTimer™) on a fee-for-service basis. NFK GreenScreen™, an assay read-out for the cancer immunotherapy drug targets IDO1 and TDO, is supplied to clients globally. For more information please visit www.ntrc.nl or contact firstname.lastname@example.org